I have always thought there was value in CYDY. I did a comparison of their Montefiore study to our Mayo study. Value was reflected for different indications. Leronlimab showed positive survival benefit to transplant patients.
Can you imagine being on an organ donor waiting list? The difficulty of reconciling your hope for an organ becoming available, and happy when one finally does, despite knowing why that developed? And then to die from complications? I seem to recall that leronlimab more than doubled the survival rate of those patients. So a small market, but tremendous promise for patients who were suffering beyond comprehension. That is an effort that I can support.
If their stock goes sub-penny, I would not mind resuming my position, if I have enough sub-pennies by that time.
I've seen some talk of a black-box warning, but I don't recall any details.
But I thought it was related to toci.
Market Data 
Markets 
AI
